Global Oral Mucositis Pipeline Review, H2 2015 - 13 Companies & 19 Drug Profiles
M2 - Wed Oct 07, 3:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fp9f5c/oral_mucositis) has announced the addition of the "Oral Mucositis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Oral Mucositis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Oral Mucositis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aldeyra Therapeutics, Inc. - Cellceutix Corporation - Clevexel Pharma SAS - Colby Pharmaceutical Company - Daewoong Pharmaceutical Co., Ltd. - Intrexon Corporation - Laila Pharmaceuticals Pvt. Ltd. - Onxeo SA - Otsuka Holdings Co., Ltd. - ProCertus BioPharm Inc. - Soligenix, Inc. - Spectrum Pharmaceuticals, Inc. - Sucampo Pharmaceuticals, Inc. Drug Profiles - AG-013 - AP-001 - AP-002 - brilacidin tetrahydrochloride - clonidine hydrochloride ER - cobiprostone - CVXL-0095 - dusquetide - GC-4403 - GC-4419 - Gene Therapy for Oral Mucositis - JVRSOD - LP-00409 - nepidermin - NS-2 - OralX - pralatrexate - rebamipide - Regenasyn For more information visit http://www.researchandmarkets.com/research/fp..._mucositis
SCMP: 18.19 (-1.21), XON: 36.01 (+1.24), SPPI: 6.20 (+0.07)
Open-Angle Glaucoma Pipeline Review, H2 2015 - 16 Companies & 21 Drug Profiles
M2 - Wed Oct 07, 3:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/55m6kn/openangle) has announced the addition of the "Open-Angle Glaucoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aerie Pharmaceuticals, Inc. - Allergan Plc - Amakem NV - Asahi Kasei Pharma Corp. - Bausch & Lomb Incorporated - F. Hoffmann-La Roche Ltd. - Inotek Pharmaceuticals Corporation - Ocular Therapeutix, Inc. - Ono Pharmaceutical Co., Ltd. - Otsuka Holdings Co., Ltd. - Oxford BioMedica Plc - Sanofi - Santen Pharmaceutical Co., Ltd. - Sun Pharmaceutical Industries Limited - Sylentis S.A. - vTv Therapeutics LLC Drug Profiles - (carteolol hydrochloride latanoprost) - (dorzolamide hydrochloride latanoprost) - (latanoprost trabodenoson) - AMA-0076 - AR-13324 - ATS-8535 - bamosiran - bimatoprost SR - DE-117 - Glaucoma-GT - HPP-851 - latanoprost - latanoprost SR - latanoprostene bunod - ONO-9054 - OPA-6566 - RO-5093151 - SAR-366234 - Small Molecules to Antagonize CXCR3 for Glaucoma - trabodenoson - travoprost SR For more information visit http://www.researchandmarkets.com/research/55m6kn/openangle
AGN: 274.84 (-1.32), VTVT: 7.07 (-0.43), ITEK: 9.63 (-0.03), AERI: 18.87 (+0.09), OCUL: 16.34 (+0.87)
Lilium Otsuka: Lilium(R) a-200, a Continuous Urine Volume Sensor, Will Be Launched in Japan
Business Wire - Fri Oct 02, 7:00AM CDT
Lilium Otsuka Co., Ltd., a subsidiary of Otsuka Holdings Co., Ltd. will begin selling the Lilium(R) a-200, a continuous, non-invasive bladder urine volume sensor, on November 2, 2015.
Global Autism Pipeline Review, H2 2015 - 19 Companies & 31 Drug Profiles
M2 - Wed Sep 23, 3:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tf7gbm/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - BioCrea GmbH - BrainStorm Cell Therapeutics Inc. - Cellceutix Corporation - Confluence Pharmaceuticals LLC - Curemark, LLC - Egenix, Inc. - F. Hoffmann-La Roche Ltd. - Heptares Therapeutics Limited - Intra-Cellular Therapies, Inc. - MedDay - Merz Pharma GmbH & Co. KgaA - Mnemosyne Pharmaceuticals, Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Retrophin Inc. - Reviva Pharmaceuticals Inc. - Saniona AB - Sumitomo Dainippon Pharma Co., Ltd. Drug Profiles - (dextromethorphan hydrobromide quinidine sulfate) - acamprosate calcium - ADX-71441 - ADX-88178 - aripiprazole - carbetocin - CM-AT - CN-2097 - Drug for Autism - HTL-14242 - ITI-007 - KM-391 - lurasidone hydrochloride - MD-1103 - memantine hydrochloride - oxytocin - RG-7314 - RO-5285119 - RP-5063 - Small Molecule to Agonize GABAA Receptor Subunit Alpha-5 for Autism - Small Molecule to Modulate GABRA5 Receptor for CNS Disorders - Small Molecule to Target GPR63 for Autism - Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism - Small Molecules to Antagonize NMDA2A for Central Nervous System Disorders - Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - Small Molecules to Inhibit Translation Initiation Factor-4E for Cancer and Autism - Small Molecules to Target Oxytocin for Autism and Anxiety Disorders - Stem Cell Therapy for Multiple Sclerosis, Rheumatoid Arthritis, Autism and Bronchopulmonary Dysplasia - Stem Cell Therapy for Neurodegenerative Disorders - suramin hexasodium - VU-0410120 For more information visit http://www.researchandmarkets.com/research/tf...m_pipeline
RTRX: 20.22 (+1.07), ITCI: 43.85 (+1.72), BCLI: 2.87 (+0.13), OMER: 12.66 (+0.58)
Retort Packaging Market by type (Pouches, Tray, and Cartons), by Material (Polyester, Polypropylene, Aluminum foil, and others), by End Use (Food, Beverage, and Others) - Global Forecast to 2020
M2 - Mon Sep 21, 6:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rf8ffb/retort_packaging) has announced the addition of the "Retort Packaging Market by type (Pouches, Tray, and Cartons), by Material (Polyester, Polypropylene, Aluminum foil, and others), by End Use (Food, Beverage, and Others) - Global Forecast to 2020" report to their offering. The global retort packaging market is projected to reach USD 41.14 Billion by 2020, with a CAGR of 6.7% from 2015 to 2020. Retort packaging is becoming popular in the frozen food and beverage market due to advantages such as the growing demand for compact and light weight packaging. The demand for retort packaging is projected to grow at a CAGR of 6.7%, in terms of value, from 2015 to 2020. Growth in the flexible packaging market and rise in the demand for ready-made meals with extended shelf life are projected to be the major drivers of the retort packaging market. The growing demand for pet food and baby food products are is also one of the major drivers of the retort packaging market. Technological advancements as well as emergence of the Meal, Ready-to-Eat and lesser logistic cost are expected to have a positive impact on the growth of the retort packaging market. The Asia-pacific region accounted for the highest share of the total market value, followed by Europe and North America due to changing lifestyle, increasing disposable income, extensive growth in population, and growth in the packaged food industry. The retort packaging market is well established in developed countries. The market in developing economies, such as China and India are estimated to grow at a higher rate from 2015 to 2020. Pouches have gained popularity due to its advantages over cans, such as reduced logistics and freight cost, consumer convenience due to reclosable feature, and extended shelf-life. Pouches are widely used in end-use applications such as tuna, pet food, soups, rice, and meat. Scope of the Report Based on Type: - Pouches - Trays - Cartons Based on Material: - Polyester - Polypropylene - Aluminum foil - Others - Nylon - Food-Grade Cast Polypropylene - Paperboard Based on End-Use: - Food - Beverage - Others - Healthcare - Personal care Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Retort Packaging Market, By Type 8 Retort Packaging Market, By Material 9 Retort Packaging Market, By End Use 10 Retort Packaging Market, By Region 11 Competitive Landscape 12 Company Profiles - Amcor Limited - Astrapak Limited - Bemis Company, Inc. - Berry Plastics Corporation - Clondalkin Industries BV - Coveris - Mondi Group - Otsuka Holdings Co., Limited - Sonoco Products Company - Tredegar Corporation For more information visit http://www.researchandmarkets.com/research/rf..._packaging
TG: 15.19 (-0.46), SON: 41.44 (+0.31), BMS: 42.33 (+0.49)
Dry (Atrophic) Macular Degeneration Market - Global Clinical Trials Review, H2, 2015
M2 - Mon Sep 14, 5:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pxt5g6/dry_atrophic) has announced the addition of the "Dry (Atrophic) Macular Degeneration Global Clinical Trials Review, H2, 2015" report to their offering. "Dry (Atrophic) Macular Degeneration Global Clinical Trials Review, H2, 2015" provides an overview of Dry (Atrophic) Macular Degeneration clinical trials scenario. This report provides top line data relating to the clinical trials on Dry (Atrophic) Macular Degeneration. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using a proprietary database - Pharma eTrack Clinical trials database. Clinical Trial Overview of Top Companies - F. Hoffmann-La Roche Ltd. - Ocata Therapeutics, Inc. - Acucela Inc. - Pfizer Inc. - Otsuka Holdings Co., Ltd. - Ophthotech Corp. - Healthcare of Today, Inc. - Allergan, Inc. - Allergan Plc - Alexion Pharmaceuticals, Inc. Clinical Trial Overview of Top Institutes / Government - University of California, Davis - Al-Azhar university - Azienda Ospedaliera Pisana - Dr. Lutfi Kirdar Kartal Training and Research Hospital - Indian Council of Medical Research - Kaplan Medical Center - National Eye Institute - University of Kentucky - University of Miami For more information visit http://www.researchandmarkets.com/research/px...y_atrophic
AGN: 274.84 (-1.32), OCAT: 4.70 (+0.02), PFE: 33.24 (+0.15), OPHT: 42.73 (+0.20), ALXN: 161.08 (-3.23)
Global Nasopharyngeal Cancer Pipeline Review 2015
M2 - Tue Sep 08, 5:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2qlv6j/nasopharyngeal) has announced the addition of the "Nasopharyngeal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Nasopharyngeal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nasopharyngeal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ambrx, Inc. - AVEO Pharmaceuticals, Inc. - BioDiem Ltd - Celgene Corporation - Cyclacel Pharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Merck & Co., Inc. - Otsuka Holdings Co., Ltd. - Pharmacyclics, Inc. - Theravectys SA - Zhejiang BetaPharma Co., Ltd. For more information visit http://www.researchandmarkets.com/research/2q...pharyngeal
PCYC: 261.25 (+1.70), CYCC: 0.53 (unch), AMBX: (), MRK: 50.95 (-0.07), AVEO: 1.27 (+0.05), GSK: 40.22 (+0.06), CELGZ: 1.74 (+0.04)
Global Cholangitis Clinical Trials Review, H1, 2015
M2 - Wed Aug 05, 5:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4zs8xp/cholangitis) has announced the addition of the "Cholangitis Global Clinical Trials Review, H1, 2015" report to their offering. Cholangitis Global Clinical Trials Review, H1, 2015 provides data on the Cholangitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cholangitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cholangitis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Cholangitis Therapeutics Clinical Trials - Genextra S.p.a. - Zambon Company S.p.A. - Shire Plc - Riemser Pharma GmbH - Otsuka Holdings Co., Ltd. - Gilead Sciences, Inc. - Fujifilm Holdings Corporation - Dr. Falk Pharma GmbH - ChemoCentryx, Inc. - Bayer AG Clinical Trial Overview of Top Institutes / Government - Mayo Clinic - Stanford University - The National Institute of Diabetes and Digestive and Kidney Diseases - Academic Medical Center - Agostino Gemelli University Polyclinic - Assistance Publique - Hopitaux de Paris - Azienda Ospedaliera di Padova - Eastern Hepatobiliary Surgery Hospital - Hokkaido University Hospital For more information visit http://www.researchandmarkets.com/research/4z...holangitis
GILD: 100.65 (-0.16), SHPG: 200.90 (-1.85), CCXI: 6.45 (+0.02)
Global Cholecystitis Clinical Trials Review, H1, 2015
M2 - Wed Aug 05, 5:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dwbp4z/cholecystitis) has announced the addition of the "Cholecystitis Global Clinical Trials Review, H1, 2015" report to their offering. Cholecystitis Global Clinical Trials Review, H1, 2015 provides data on the Cholecystitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cholecystitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cholecystitis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Cholecystitis Therapeutics Clinical Trials - Pfizer Inc. - Johnson & Johnson - Bayer AG - USGI Medical, Inc. - Otsuka Holdings Co., Ltd. - Novartis AG - Fujifilm Holdings Corporation Clinical Trial Overview of Top Institutes / Government - Karolinska University Hospital l - Mansoura University - St. Antonius Hospital - Tehran University of Medical Sciences - Asan Medical Center - Babol University of Medical Sciences - Beijing You An Hospital, Capital Medical University - Bezmialem Vakif University - Centre Hospitalier Universitaire, Amiens - Chiba University For more information visit http://www.researchandmarkets.com/research/dw...lecystitis
JNJ: 95.37 (+0.29), PFE: 33.24 (+0.15), NVS: 91.90 (-0.71)
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2015 - 30 Companies & 52 Drug Profiles
M2 - Fri Jul 31, 9:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/57stt9/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alcobra Ltd - Amarantus Bioscience Holdings, Inc. - Arbor Pharmaceuticals, LLC. - Cerecor Inc. - Collegium Pharmaceutical, Inc. - Curemark, LLC - DURECT Corporation - Eli Lilly and Company - H. Lundbeck A/S - Hisamitsu Pharmaceutical Co., Inc. - Integrative Research Laboratories Sweden AB - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Merck & Co., Inc. - Mnemosyne Pharmaceuticals, Inc. - Neos Therapeutics, Inc. - NeuroDerm Ltd. - Otsuka Holdings Co., Ltd. - P2D Bioscience - Polleo Pharma Limited - Reviva Pharmaceuticals Inc. - Samyang Biopharmaceuticals Corporation - Shire Plc - Signature Therapeutics, Inc - Sunovion Pharmaceuticals Inc. - Supernus Pharmaceuticals, Inc. - Taisho Pharmaceutical Co., Ltd. - Takeda Pharmaceutical Company Limited - Tris Pharma, Inc. - Vernalis Plc For more information visit http://www.researchandmarkets.com/research/57...on_deficit
KMPH: 18.83 (-0.18), ADHD: 5.66 (+0.17), SUPN: 14.48 (+0.16), COLL: 20.67 (-0.19), LLY: 86.14 (+2.37), DRRX: 2.13 (+0.02), NEOS: 18.69 (-0.57), NDRM: 22.56 (-0.09), SHPG: 200.90 (-1.85), MRK: 50.95 (-0.07), ITCI: 43.85 (+1.72)
Atherosclerosis Pipeline Review, H1 2015 - 42 Companies & 105 Drug Profiles
M2 - Fri Jul 31, 8:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pfrcbq/atherosclerosis) has announced the addition of the "Atherosclerosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Atherosclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atherosclerosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ache Laboratorios Farmaceuticos S/A - advanceCor GmbH - AFFiRiS AG - Arisaph Pharmaceuticals, Inc. - Artery Therapeutics, Inc. - AstraZeneca Plc - Athera Biotechnologies AB - AtheroNova Inc. - AuraSense Therapeutics, LLC - Bayer AG - Bridge Bioresearch Plc - Campus Technologies Freiburg GmbH - Cardax Pharmaceuticals, Inc. - ChemoCentryx, Inc. - CohBar Inc. - DoNatur GmbH - Dr. Reddy's Laboratories Limited - Dybly AG - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GenKyoTex S.A. - Gilead Sciences, Inc. - Isis Pharmaceuticals, Inc. - Jenrin Discovery, Inc. - Johnson & Johnson - KineMed, Inc. - Kowa Company, Ltd. - Lead Discovery Center GmbH - MedImmune, LLC - Merck & Co., Inc. - MI.TO. Technology S.r.L. - Novartis AG - Omeros Corporation - OPKO Health, Inc. - Otsuka Holdings Co., Ltd. For more information visit http://www.researchandmarkets.com/research/pf...osclerosis
KNMD: (), LLY: 86.14 (+2.37), OMER: 12.66 (+0.58), JNJ: 95.37 (+0.29), ISIS: 43.24 (+0.86), OPK: 8.90 (+0.26), GILD: 100.65 (-0.16), AZN: 32.23 (-0.16), MRK: 50.95 (-0.07), CCXI: 6.45 (+0.02), NVS: 91.90 (-0.71)
Migraine Pipeline Review, H1 2015: 38 Companies & 56 Drug Profiles
M2 - Fri Jul 31, 8:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wdkbnx/migraine) has announced the addition of the "Migraine - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ache Laboratorios Farmaceuticos S/A - Acorda Therapeutics, Inc. - Alder Biopharmaceuticals Inc. - Allergan, Inc. - Amgen Inc. - Astellas Pharma Inc. - BioDelivery Sciences International, Inc. - Biofrontera AG - Bristol-Myers Squibb Company - Charleston Laboratories, Inc. - CoLucid Pharmaceuticals, Inc. - D-Pharm Ltd. - Dr. Reddy's Laboratories Limited - Eli Lilly and Company - Heptares Therapeutics Limited - iCeutica, Inc. - Mallinckrodt Plc - Medestea Research & Production S.p.A. - Merck & Co., Inc. - Monosol Rx, LLC - NAL Pharmaceuticals Ltd. - Nektar Therapeutics - NeurAxon, Inc. - Northern Light Pharmaceuticals AB - Noxxon Pharma AG - Otsuka Holdings Co., Ltd. - Paladin Labs Inc. - Pantarhei Bioscience BV - Pivot Pharmaceuticals Inc - Pozen, Inc. - RedHill Biopharma Ltd. - Revance Therapeutics, Inc. - Shin Nippon Biomedical Laboratories, Ltd. - Suda Ltd - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/wdkbnx/migraine
BDSI: 6.74 (+0.22), RDHL: 12.80 (+0.53), AMGN: 149.59 (-0.31), LLY: 86.14 (+2.37), ACOR: 29.89 (-0.22), BMY: 61.44 (+0.93), NKTR: 11.34 (+0.56), AGN: 274.84 (-1.32), ALDR: 28.80 (-0.56), CLCD: 4.00 (-0.23), MRK: 50.95 (-0.07), TEVA: 58.96 (-0.28), RVNC: 30.89 (+0.83), POZN: 6.29 (+0.10)
Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Wed Jul 29, 11:30AM CDT
The report "Atherosclerosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Atherosclerosis. Atherosclerosis is a slow, progressive disease that may start in childhood. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on Atherosclerosis Pipeline with 78 market data tables and 15 figures, spread across 276 pages is available at http://www.rnrmarketresearch.com/atherosclero...eport.html .
VCEL: 2.52 (+0.08), KNMD: (), VTAE: 13.00 (+0.10), LLY: 86.14 (+2.37), OMER: 12.66 (+0.58), JNJ: 95.37 (+0.29), ISIS: 43.24 (+0.86), OPK: 8.90 (+0.26), GILD: 100.65 (-0.16), AZN: 32.23 (-0.16), MRK: 50.95 (-0.07), CCXI: 6.45 (+0.02), VBLT: 7.35 (-0.23), NVS: 91.90 (-0.71)
Ascites Global Clinical Trials Review, H1, 2015
M2 - Mon Jul 27, 7:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4zf7gm/ascites_global) has announced the addition of the "Ascites Global Clinical Trials Review, H1, 2015" report to their offering. "Ascites Global Clinical Trials Review, H1, 2015" provides data on the Ascites clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ascites. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ascites. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies / Institutions - Sanofi - Otsuka Holdings Co., Ltd. - Simcere Pharmaceutical Group - Shire Plc - Neovii Biotech GmbH - Neopharm Ltd. - Grifols, S.A. - Ferring International Center S.A. . - Anthera Pharmaceuticals Inc. - Govind Ballabh Pant Hospital - Otsuka Beijing Research Institute - The University of Tokyo - Austin Health - Azienda Ospedaliero Universitaria molinette San Giovanni Battista di Torino - Boston Medical Center - Chinese PLA General Hospital - Copenhagen University Hospital Hvidovre - Dong-A University For more information visit http://www.researchandmarkets.com/research/4z...tes_global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ANTH: 6.12 (+0.12), SHPG: 200.90 (-1.85)
Otsuka Holdings Co., Ltd. - Product Pipeline Review - 2015
PR Newswire - Thu Jul 23, 8:30AM CDT
Summary
Major Depressive Disorder Pipeline Review, H1 2015 - 37 Companies & 32 Drug Profiles
M2 - Tue Jul 21, 10:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m6wpzn/major_depressive) has announced the addition of the "Major Depressive Disorder - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Major Depressive Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Major Depressive Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actavis plc - Alkermes Plc - Angelini Group - Azevan Pharmaceuticals, Inc. - BioCrea GmbH - Bristol-Myers Squibb Company - Cerecor Inc. - e-Therapeutics plc - Edgemont Pharmaceuticals, LLC - Eli Lilly and Company - Euthymics Bioscience, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - H. Lundbeck A/S - Hua Medicine Ltd. - Intas Pharmaceuticals Ltd. - Intra-Cellular Therapies, Inc. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Johnson & Johnson - Lead Discovery Center GmbH - Luye Pharma Group Ltd. - Methylation Sciences Inc. - miCure Therapeutics Ltd. - Mitsubishi Tanabe Pharma Corporation - Naurex, Inc. - Neuralstem, Inc. - nLife Therapeutics, S.L. - Otsuka Holdings Co., Ltd. - Pherin Pharmaceuticals, Inc. - Reviva Pharmaceuticals Inc. - Richter Gedeon Nyrt. - Saniona AB - Sumitomo Dainippon Pharma Co., Ltd. - Sunovion Pharmaceuticals Inc. - Suven Life Sciences Ltd. Drug Profiles - (aripiprazole sertraline) - (samidorphan buprenorphine hydrochloride) - amitifadine - AN-788 - aripiprazole - AV-101 - AVP-786 - basimglurant - brexpiprazole - bupropion hydrochloride ER - cariprazine - CERC-301 - desvenlafaxine succinate SR - EDG-005 - edivoxetine - esketamine hydrochloride - INASTR-001 - ITI-007 - lurasidone hydrochloride - LY-03005 - LY-2940094 - MIN-117 - miR-135 - MSI-195 - NLF-NEU - NRX-1074 - NSI-189 - onabotulinumtoxin A - PH-10 - rapastinel - RP-5063 - SEP-363856 For more information visit http://www.researchandmarkets.com/research/m6...depressive
JNJ: 95.37 (+0.29), ITCI: 43.85 (+1.72), LLY: 86.14 (+2.37), GSK: 40.22 (+0.06), BMY: 61.44 (+0.93), ALKS: 60.82 (+0.92), CUR: 1.33 (+0.03)
Epithelial Ovarian Cancer Pipeline Review 2015 - 49 Companies & 69 Drug Profiles
M2 - Tue Jul 21, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/snr9r3/epithelial) has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Adaptimmune Limited - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - Bayer AG - Bionomics Limited - BioNumerik Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Celldex Therapeutics, Inc. - Celon Pharma Sp. z o.o. - Celsion Corporation - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Glycotope GmbH - ImmunoGen, Inc. - Immunotope, Inc. - Johnson & Johnson - MabVax Therapeutics Holdings, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - NeoStem, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OBI Pharma, Inc. - Oncobiologics, Inc. - Oncolytics Biotech Inc. - Onxeo SA - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Pharma Mar, S.A. For more information visit http://www.researchandmarkets.com/research/snr9r3/epithelial
CLDX: 12.80 (+1.06), NBS: 2.25 (-0.09), CLSN: 1.84 (+0.14), JNJ: 95.37 (+0.29), ABBV: 55.64 (-0.40), EXEL: 5.99 (+0.14), ONCY: 0.45 (unch), CERU: 3.65 (+0.07), PFE: 33.24 (+0.15), IMGN: 10.91 (+0.25), AMGN: 149.59 (-0.31), LLY: 86.14 (+2.37), CLVS: 93.60 (+3.62), AZN: 32.23 (-0.16), MRK: 50.95 (-0.07), NVS: 91.90 (-0.71)
Polycystic Kidney Disease Therapeutics Pipeline Review, H1 2015 - 8 Companies & 17 Drug Profiles
M2 - Tue Jul 21, 3:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ts2kkp/polycystic_kidney) has announced the addition of the "Polycystic Kidney Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Polycystic Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Kidney Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - DiscoveryBiomed, Inc. - Endocyte, Inc. - IC-MedTech, Inc. - Ipsen S.A. - Kadmon Corporation, LLC - Metabolic Solutions Development Company, LLC - Otsuka Holdings Co., Ltd. - Synta Pharmaceuticals Corp. Drug Profiles - (ascorbic acid menadione) - DBM-43H11 - Drugs for Polycystic Kidney Disease - EC-0371 - JP-153 - lanreotide acetate - MSDC-0160 - MSDC-0602 - Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Small Molecule to Inhibit Xanthine Oxidase for Polycystic Kidney Disease - Small Molecules to Activate AMPK for Polycystic Kidney Disease - Small Molecules to Activate Somatostatin Receptor Type 4 for Oncology, Genito Urinary System And Sex Hormones and Metabolic Disorders - Small Molecules to Inhibit Hsp90 for Polycystic Kidney Disease - Small Molecules to Target CIL-1 for Genetic Disorders and Polycystic Kidney Disease - STA-2842 - tesevatinib tosylate - tolvaptan For more information visit http://www.researchandmarkets.com/research/ts...tic_kidney
SNTA: 1.97 (-0.01), ECYT: 4.76 (+0.08)
Endometrial Cancer Therapeutics Pipeline Review, H1 2015 - 35 Companies & 48 Drug Profiles
M2 - Tue Jul 21, 3:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/psfwd9/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Aeterna Zentaris Inc. - Ariad Pharmaceuticals, Inc. - Arno Therapeutics, Inc. - ArQule, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BioMarin Pharmaceutical Inc. - Boehringer Ingelheim GmbH - Critical Outcome Technologies Inc. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Farmsintez - Galena Biopharma, Inc. - Genentech, Inc. - Genmab A/S - GlaxoSmithKline Plc - Gradalis Inc. - ImmunoGen, Inc. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Novartis AG - OncoHoldings, Inc. - Oncothyreon Inc. - Otsuka Holdings Co., Ltd. - Pharma Mar, S.A. - Puma Biotechnology, Inc. - Sanofi - Scancell Holdings Plc - Shenogen Pharma Group Ltd. Drug Profiles - (ponatinib hydrochloride ridaforolimus) - ???Pb-TCMC-Trastuzumab - AEZS-125 - afuresertib hydrochloride trametinib dimethyl sulfoxide - ARQ-092 - AV-203 - AZD-2014 - AZD-5363 - buparlisib hydrochloride - cabozantinib s-malate - cancer vaccine - Cell Therapy for Oncology - CLR-457 - COTI-2 - cridanimod - dalantercept - EP-200 - epacadostat - everolimus - FROST-450 - GALE-301 - GDC-0927 - GSK-2636771 - HO-3867 - HuMax-TF-ADC - INCB-54828 - lenvatinib - lurbinectedin - mirvetuximab soravtansine - MK-2206 - Modi-1 - Monoclonal Antibody to Inhibit L1CAM for Ovarian and Endometrial Cancer - neratinib - nintedanib - onapristone ER For more information visit http://www.researchandmarkets.com/research/ps...ndometrial
BMRN: 102.69 (+1.97), ARQL: 2.04 (+0.05), GALE: 1.74 (+0.01), EXEL: 5.99 (+0.14), XLRN: 24.08 (-0.18), INCY: 105.00 (+1.56), IMGN: 10.91 (+0.25), GSK: 40.22 (+0.06), ONTY: 2.88 (+0.08), AZN: 32.23 (-0.16), MRK: 50.95 (-0.07), AVEO: 1.27 (+0.05), PBYI: 79.41 (+3.89), KPTI: 11.75 (+0.04), NVS: 91.90 (-0.71)
Bipolar Disorder (Manic Depression) Therapeutics Pipeline Review, H1 2015 - 23 Companies & 29 Drug Profiles
M2 - Tue Jul 21, 3:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hs6grh/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ascendis Pharma A/S - AstraZeneca PLC - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Delpor, Inc. - Eli Lilly and Company - Intas Pharmaceuticals Ltd. - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - MarcoPolo Pharmaceuticals SA - Navigen Pharmaceuticals, Inc. - Neurocrine Biosciences, Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Reviva Pharmaceuticals Inc. - Richter Gedeon Nyrt. - SK Biopharmaceuticals Co., Ltd. - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries Limited - Zogenix, Inc. - Zysis Limited Drug Profiles - ACP-005 - aripiprazole - aripiprazole CR - BRDK-98958073 - cariprazine - CNV-1061436 - DP-VPA - Drug for Bipolar Disorder - Drug for Cancer and Neurodegenerative Disease - Endoxifen - ITI-007 - KP-303 - lurasidone hydrochloride - LY-2979165 - NP-202 - paliperidone palmitate - PGW-5 - quetiapine fumarate ER - ramelteon - risperidone - RP-5063 - SKL-PSY - Small Molecule to Antagonize GPR78 for Bipolar Disorder and Schizophrenia - Small Molecule to Inhibit VMAT-2 for Schizophrenia, Bipolar Disorder and Movement Disorders - Small Molecule to Target GPR50 for CNS and Metabolic Disorders - Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Synthetic Peptides to Inhibit IMPase for Bipolar Disorder - uridine triacetate - ziprasidone hydrochloride For more information visit http://www.researchandmarkets.com/research/hs...r_disorder
NBIX: 46.10 (+2.50), KMPH: 18.83 (-0.18), ASND: 17.24 (+0.05), ZGNX: 13.80 (+0.78), PFE: 33.24 (+0.15), AZN: 32.23 (-0.16), TEVA: 58.96 (-0.28), ITCI: 43.85 (+1.72), LLY: 86.14 (+2.37), OMER: 12.66 (+0.58)